Search

Displaying results 1161 - 1170 of 10000 in total
  1. Drug

    Sevoflurane

    go.drugbank.com/drugs/DB01236
    ApprovedInvestigationalVet approved

    [L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. … Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesProducts: SOJOURN % 100 INHALASYON COZELTISİ 250 ML, SEVORANE %100 İNHALASYON ÇÖZELTİSİ, 250 ML
  2. Drug

    Prednisolone hemisuccinate

    go.drugbank.com/drugs/DB14633
    Investigational

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersProducts: Prednisolut 100 mg Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung, Prednisolut 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung
  3. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).

    Products: Imjudo Concentrate for Solution for Intravenous Infusion 20 mg/mL, Imjudo 300 mg/15 ml İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 adet
  4. Drug

    Petrolatum

    go.drugbank.com/drugs/DB11058
    ApprovedInvestigational

    It is used as an ointment base, topical protectant, and lubricant.

    Mixtures: PCP 100 Kit, Carmex 10 Count Variety Pack SPF 15 SunscreenSynonyms: Petrolatum base
  5. Drug

    Tenofovir alafenamide

    go.drugbank.com/drugs/DB09299
    ApprovedInvestigational

    [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271] … [A178219] It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil.

    Mixtures: BİKTARVY 50 MG / 200 MG / 25 MG FİLM KAPLI TABLET, 30 TABLET, BİKTARVY 50 MG / 200 MG / 25 MG FİLM KAPLI TABLET, 90 TABLETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. … It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced.

    Products: EPORON 10000 IU/1,0 ML KULLANIMA HAZIR 10 ENJEKTOR, EPORON 2000 IU/0,5 ML KULLANIMA HAZIR 10 ENJEKTOR
  7. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine was discovered at Janssen Pharmaceutica in 1979.

    Products: Livostin Sus Nas 0.5mg/ml, Levocamed 0,5 mg/ml Augentropfensuspension
  8. Drug

    Lansoprazole

    go.drugbank.com/drugs/DB00448
    ApprovedInvestigational

    Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole.

    Mixtures: TRILEVO 500 MG+30 MG+ 1000 MG TEDAVİ PAKETİ, TRIO 1000 MG + 500 MG + 30 MG TEDAVİ PAKETİ, 6X7 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C18 Substrates
  9. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares.

    Products: Spevigo 450 mg/7,5 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 2 ADET
  10. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    [L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsProducts: CERDELGA 84 MG SERT KAPSÜL, 56 ADET, ELUXAT 84 MG SERT KAPSÜL